Serious concerns could delay Zocor switch
March 17, 2004Serious concerns have been expressed about plans to sell statins over the counter, and could hold up the POM to …
Novartis ponders tie-up with Aventis
March 8, 2004Aventis may have found its 'white knight' to save it from a hostile takeover from Sanofi-Synthelabo, in the shape of …
MMR researchers withdraw claim
March 4, 2004MMR
Ten doctors who co-authored the controversial UK study which linked the MMR jab to autism have withdrawn their support for …
Making the most of CRM
March 4, 2004In recent years, pharma companies have spent considerable sums on introducing customer relationship management (CRM). However, our research into the …
Elan fall-out provides launch pad for new company
March 4, 2004The withdrawal of Elan from Europe has provided a new platform for the launch of a new niche player in …
McClellan’s new job stirs political controversy
March 2, 2004The head of the FDA Mark McClellan is to quit his post in order to lead the reform of the …
Yamanouchi to buy rivals Fujisawa for $7 billion
February 26, 2004Japan's third largest pharmaceutical company Yamanouchi is to buy its national rival Fujisawa in a deal worth around $7.7 billion.Rumours …
Persistence pays off as Erbitux finally wins approval
February 23, 2004Erbitux, the colorectal cancer drug once blighted by one of the biggest ever regulatory scandals has been granted marketing approval …
Cystic fibrosis inhaler to gain European approvals
February 23, 2004UK drug delivery specialist Profile Therapeutics says it expects marketing approval for its new inhaled cystic fibrosis drug in eight …
Fast track surgery supplier chosen
February 19, 2004Mercury Healthcare has been chosen as the preferred supplier to run five new NHS fast-track surgery centres.Routine general surgery will …
Latest content
FibroFind appoints Lee Borthwick as CEO
